Weight Watchers Expands GLP-1 Access for Medicare Beneficiaries
Event summary
- Weight Watchers Med+ partners with Medicare to offer GLP-1 medications at $50/month under the Medicare GLP-1 Bridge Program, running from July 2026 to December 2027.
- Eligible beneficiaries can access Zepbound®, KwikPen®, Foundayo®, and Wegovy® through the program with support for insurance navigation and prior authorizations.
- Weight Watchers reports that Med+ members using GLP-1 medications alongside behavioral support lost 29.1% more body weight on average at 12 months compared to those without support.
The big picture
Weight Watchers is leveraging its established brand trust among older adults to expand into the GLP-1 medication market, a rapidly growing segment of the healthcare industry. The Medicare GLP-1 Bridge Program positions Weight Watchers as a key player in providing accessible weight management solutions for seniors, aligning with broader trends toward personalized and integrated health services.
What we're watching
- Program Adoption
- The pace at which Medicare beneficiaries enroll in the GLP-1 Bridge Program will determine its success and impact on Weight Watchers' revenue.
- Regulatory Dynamics
- Whether Medicare policy changes could extend or alter the program's terms beyond December 2027, affecting long-term strategy.
- Competitive Positioning
- How Weight Watchers' integrated approach to GLP-1 medications and behavioral support differentiates it from competitors in the weight management space.
Related topics